Controversial Guinea-Bissau Vaccine Trial Suspended Amid Global Ethics Concerns

A proposed United States-funded clinical trial investigating the hepatitis B vaccine in Guinea-Bissau has been suspended following widespread international criticism over its ethical basis and scientific justification. The study, which would have involved approximately 14,000 newborns, has triggered significant debate about power imbalances in global health research and the protection of vulnerable populations.

The trial was designed by researchers at the University of Southern Denmark and funded by the US Centers for Disease Control and Prevention. The research aimed to test whether administering the hepatitis B vaccine at birth versus at six weeks of age has different long-term health outcomes. In Guinea-Bissau, where hepatitis B affects between 18 and 19 per cent of the adult population, the study would have provided half of enrolled infants with the vaccine at birth and the other half at six weeks.

However, the study design has drawn criticism from the World Health Organization, African scientists, and global health experts. The core concern centres on whether it is ethically acceptable to delay a vaccine that the WHO recommends should be given within 24 hours of birth, particularly in a country with such high hepatitis B prevalence.

The WHO has stated it has significant concerns about the study’s scientific justification and ethical safeguards. According to the organisation, there is no scientific necessity for withholding the birth dose from half the participants, as the hepatitis B vaccine’s safety and effectiveness are already well-established. The WHO has emphasised that clinical trials involving placebo or no-treatment arms are only acceptable when no proven intervention exists or when such a design is essential to answer a critical safety question.

The trial’s design also raises concerns about informed consent. Mothers would not have received comprehensive information about the study’s risks, potentially constraining their decision-making ability as key responsible parties for their infants’ wellbeing. Additionally, by delaying vaccination in half the study group, some babies born to hepatitis B-infected mothers could face heightened risk of mother-to-infant transmission during their most vulnerable weeks of life.

The comparison to the Tuskegee Syphilis Study, an infamous 40-year experiment conducted by the US Public Health Service on African American men without informed consent, has added weight to concerns. That study withheld proven treatment from participants and resulted in deaths and long-term health consequences. The parallel has sparked particular concern given historical patterns of exploitative research on Black communities and ongoing global health inequities.

The University of Southern Denmark announced in March 2026 that it has placed the study “on full hold” pending clarification of its ethical basis. The decision followed revelations about irregularities in the initial approval process in Guinea-Bissau. According to reporting, the local ethics committee continued using the signature of a former ethics board president on approval documents long after he had resigned. The committee also had only four active members at the time of approval, despite requiring six.

The WHO Research Ethics Review Committee will now conduct an independent assessment of the trial. Guinea-Bissau’s government has formally suspended the study pending further technical reviews. The country had previously planned to introduce hepatitis B birth-dose vaccination by 2028, having decided in 2024 to add the vaccine to its national immunisation schedule.

US Department of Health and Human Services officials have taken a distancing stance, stating that the CDC is reviewing whether the trial could still receive proper approval in Guinea-Bissau, but they have not directly addressed criticisms regarding the trial’s scientific merit or ethical basis.

This controversy reflects longstanding tensions in international health research governance, particularly regarding how research is conducted in low-income countries. Whilst the trial’s suspension addresses immediate safety concerns, experts have noted that the response highlights deeper structural issues in how procedural ethics are applied globally. The trial had previously passed multiple ethical reviews before public criticism emerged, revealing gaps between formal approval processes and broader public legitimacy.

The incident also raises questions about power dynamics in health research partnerships. Critics argue that research priorities, funding decisions, and trial designs should involve meaningful participation from communities and countries where studies are conducted, rather than being determined primarily by researchers and funding bodies from high-income nations.

Health officials have emphasised that hepatitis B vaccination remains essential. The virus causes more than one million deaths annually and poses especially high risks to newborns, who can develop lifelong infections if exposed early.

Key Takeaways

• A controversial US-funded hepatitis B vaccine trial in Guinea-Bissau has been suspended following international ethics concerns and comparisons to historical unethical research on Black communities
• The WHO, African scientists, and global health experts criticised the study’s design for potentially withholding a proven, safe vaccine from vulnerable infants without adequate scientific justification
• Irregularities in the local approval process, including use of a resigned committee member’s signature, have prompted an independent WHO ethics review
• The suspension highlights persistent challenges in ensuring equitable, ethical global health research governance

What This Means for Kent Residents

Whilst this trial was proposed for West Africa, the ethical principles at stake—informed consent, protection of vulnerable populations, and scientific integrity—underpin all healthcare research globally, including studies conducted through the NHS. Kent residents participating in clinical trials through NHS England services benefit from stringent ethical oversight by research ethics committees and institutional review boards. The Medicines and Healthcare Products Regulatory Agency and the Health Research Authority oversee UK clinical research to ensure patient safety and rights are protected. If you have concerns about research ethics or wish to report concerns about a clinical trial, NHS England services and local hospital trusts, including East Kent Hospitals University NHS Foundation Trust and Maidstone and Tunbridge Wells NHS Trust, can provide guidance. Your GP can also advise on participation in clinical research.